{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:59:01Z","timestamp":1793059141144,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01389-0","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:35:17Z","timestamp":1769067317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Review of First-Generation Obesity Medications"],"prefix":"10.1007","volume":"28","author":[{"given":"Sarah H.","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"1389_CR1","unstructured":"Organization WH. Obesity and overweight. 2025.\u00a0https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed July 27 2025."},{"key":"1389_CR2","unstructured":"Health Risks of Overweight & Obesity. https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/adult-overweight-obesity\/health-risks#type2diabetes."},{"issue":"3","key":"1389_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/s2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1389_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.05.024","author":"O Gilbert","year":"2025","unstructured":"Gilbert O, Gulati M, Gluckman TJ, Kittleson MM, Rikhi R, Saseen JJ, et al. 2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health. JACC. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.024.","journal-title":"JACC"},{"issue":"4","key":"1389_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/00325481.2022.2051366","volume":"134","author":"DB Horn","year":"2022","unstructured":"Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359\u201375. https:\/\/doi.org\/10.1080\/00325481.2022.2051366.","journal-title":"Postgrad Med"},{"key":"1389_CR6","unstructured":"Xenical. (orlistat) [package insert]. San Francisco, CA: Genentech USA, Inc. 1999."},{"issue":"3","key":"1389_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","volume":"24","author":"N Finer","year":"2000","unstructured":"Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a Gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306\u201313. https:\/\/doi.org\/10.1038\/sj.ijo.0801128.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1389_CR8","unstructured":"Adipex-p. (phentermine) [package insert]. Sellersville, PA: Teva Pharmaceuticals. 2012."},{"issue":"11","key":"1389_CR9","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obes (Silver Spring). 2013;21(11):2163\u201371. https:\/\/doi.org\/10.1002\/oby.20584.","journal-title":"Obes (Silver Spring)"},{"key":"1389_CR10","volume-title":"And topiramate extended-release) [package insert]","author":"Qsymia (phentermine","year":"2012","unstructured":"Qsymia (phentermine. And topiramate extended-release) [package insert]. Winchester, KY: VIVUS Inc. 2012."},{"issue":"2","key":"1389_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obes (Silver Spring). 2012;20(2):330\u201342. https:\/\/doi.org\/10.1038\/oby.2011.330.","journal-title":"Obes (Silver Spring)"},{"key":"1389_CR12","unstructured":"Contrave (naltrexone HCL. and bupropion HCL) [package insert] San Diego, CA: Nalpropion Pharmaceuticals, Inc. 2014."},{"issue":"9741","key":"1389_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of Naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(10)60888-4.","journal-title":"Lancet"},{"key":"1389_CR14","unstructured":"Saxenda. (liraglutide) [package insert]. Plainsboro, NJ: Novo Nordisk. 2020."},{"issue":"1","key":"1389_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"1","key":"1389_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of Orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155\u201361. https:\/\/doi.org\/10.2337\/diacare.27.1.155.","journal-title":"Diabetes Care"},{"key":"1389_CR17","unstructured":"Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. (1474-547X (Electronic))."},{"issue":"7631","key":"1389_CR18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194\u20139. https:\/\/doi.org\/10.1136\/bmj.39385.413113.25.","journal-title":"BMJ"},{"issue":"5","key":"1389_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA clinical practice guideline on Pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198\u2013225. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.045.","journal-title":"Gastroenterology"},{"issue":"4","key":"1389_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/oby.22430","volume":"27","author":"KH Lewis","year":"2019","unstructured":"Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of Longer-Term phentermine use: clinical outcomes from an electronic health record cohort. Obes (Silver Spring). 2019;27(4):591\u2013602. https:\/\/doi.org\/10.1002\/oby.22430.","journal-title":"Obes (Silver Spring)"},{"issue":"9774","key":"1389_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(11)60205-5.","journal-title":"Lancet"},{"issue":"2","key":"1389_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308. https:\/\/doi.org\/10.3945\/ajcn.111.024927.","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"1389_CR23","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of Naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obes (Silver Spring). 2013;21(5):935\u201343. https:\/\/doi.org\/10.1002\/oby.20309.","journal-title":"Obes (Silver Spring)"},{"issue":"1","key":"1389_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with Naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obes (Silver Spring). 2011;19(1):110\u201320. https:\/\/doi.org\/10.1038\/oby.2010.147.","journal-title":"Obes (Silver Spring)"},{"issue":"12","key":"1389_CR25","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of Naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022\u20139. https:\/\/doi.org\/10.2337\/dc13-0234.","journal-title":"Diabetes Care"},{"issue":"7","key":"1389_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399. https:\/\/doi.org\/10.1001\/jama.2015.9676.","journal-title":"JAMA"},{"key":"1389_CR27","doi-asserted-by":"crossref","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. 2013.","DOI":"10.1038\/ijo.2013.148"},{"issue":"4","key":"1389_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"25 Suppl 2","key":"1389_CR29","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American college of Cardiology\/American heart association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102\u201338. https:\/\/doi.org\/10.1161\/01.cir.0000437739.71477.ee.","journal-title":"Circulation"},{"issue":"Supplement1","key":"1389_CR30","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in Diabetes\u20132025. Diabetes Care. 2024;48(Supplement1):S167\u201380. https:\/\/doi.org\/10.2337\/dc25-S008.","journal-title":"Diabetes Care"},{"issue":"11","key":"1389_CR31","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.eprac.2021.07.004","volume":"27","author":"J MacEwan","year":"2021","unstructured":"MacEwan J, Kan H, Chiu K, Poon JL, Shinde S, Ahmad NN. Antiobesity medication use among overweight and obese adults in the united states: 2015\u20132018. Endocr Pract. 2021;27(11):1139\u201348. https:\/\/doi.org\/10.1016\/j.eprac.2021.07.004.","journal-title":"Endocr Pract"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01389-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:35:22Z","timestamp":1769067322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01389-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01389-0","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14"}}